BC
Broadfin Capital Portfolio holdings
AUM
$403M
This Quarter Return
+22.65%
1 Year Return
+74.97%
3 Year Return
+245.63%
5 Year Return
+336.04%
10 Year Return
–
AUM
$1.03B
AUM Growth
+$1.03B
(+36%)
Cap. Flow
+$160M
Cap. Flow
% of AUM
15.54%
Top 10 Holdings %
Top 10 Hldgs %
40.17%
Holding
97
New
37
Increased
21
Reduced
20
Closed
12
Top Buys
| 1 |
Travere Therapeutics
TVTX
|
$34.1M |
| 2 |
Heron Therapeutics
HRTX
|
$31.1M |
| 3 |
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
|
$21M |
| 4 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$20.1M |
| 5 |
Emergent Biosolutions
EBS
|
$18.5M |
Top Sells
| 1 |
Teva Pharmaceuticals
TEVA
|
$29.1M |
| 2 |
LCI
Lannett Company, Inc.
LCI
|
$23.4M |
| 3 |
Assertio
ASRT
|
$22.5M |
| 4 |
NVDQ
Novadaq Technologies Inc.
NVDQ
|
$16.6M |
| 5 |
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
|
$14.9M |
Sector Composition
| 1 | Healthcare | 79.95% |
| 2 | Technology | 0.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
1
Avadel Pharmaceuticals
AVDL
$1.43B
| $70.6M | 6.84% | 5,267,911 +1,500,000 | +40% | +$20.1M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $65.1M | 6.31% | 4,305,469 +48,000 | +1% | +$726K |
|
|
3
Assertio
ASRT
$80.4M
| $46.3M | 4.48% | 3,190,816 -1,553,956 | -33% | -$22.5M |
|
|
4
Emergent Biosolutions
EBS
$443M
| $45.6M | 4.42% | 1,805,352 +731,304 | +68% | +$18.5M |
|
5
AngioDynamics
ANGO
$417M
| $40.8M | 3.96% | 2,592,649 +95,600 | +4% | +$1.51M |
|
|
6
Travere Therapeutics
TVTX
$1.56B
| $34.1M | 3.31% | +1,609,696 | New | +$34.1M |
|
|
7
Heron Therapeutics
HRTX
$207M
| $31.1M | 3.01% | +2,233,173 | New | +$31.1M |
|
|
BDSI
8
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $29.3M | 2.84% | 3,472,054 +1,250,000 | +56% | +$10.5M |
|
|
NVDQ
9
DELISTED
Novadaq Technologies Inc.
NVDQ
| $27.3M | 2.65% | 1,226,617 -743,017 | -38% | -$16.6M |
|
|
LCI
10
DELISTED
Lannett Company, Inc.
LCI
| $24.4M | 2.37% | 683,564 -656,381 | -49% | -$23.4M |
|
|
PGNX
11
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $22.8M | 2.21% | 5,586,169 +1,586,169 | +40% | +$6.49M |
|
|
TTPH
12
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
| $21.9M | 2.12% | 2,008,125 -185,203 | -8% | -$2.02M |
|
|
DSCI
13
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
| $21.2M | 2.05% | 1,669,777 +798,179 | +92% | +$10.1M |
|
14
Rigel Pharmaceuticals
RIGL
$697M
| $21.2M | 2.05% | 5,455,119 +500,000 | +10% | +$1.94M |
|
|
CTRX
15
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
| $21M | 2.03% | +468,263 | New | +$21M |
|
|
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $20M | 1.94% | 1,000,869 -516,362 | -34% | -$10.3M |
|
|
NTUS
17
DELISTED
Natus Medical Inc
NTUS
| $19.7M | 1.91% | 764,915 -249,201 | -25% | -$6.43M |
|
|
WINT
18
DELISTED
Windtree Therapeutics Inc
WINT
| $17.3M | 1.68% | 8,066,000 | – | – |
|
|
AMAG
19
DELISTED
AMAG Pharmaceuticals, Inc.
AMAG
| $16.8M | 1.63% | +867,117 | New | +$16.8M |
|
|
IPXL
20
DELISTED
Impax Laboratories, Inc.
IPXL
| $16.7M | 1.62% | 633,929 -100,000 | -14% | -$2.64M |
|
|
AEGR
21
DELISTED
Aegerion Pharmaceuticals, Inc.
AEGR
| $16.2M | 1.57% | +350,000 | New | +$16.2M |
|
|
INFI
22
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $15.8M | 1.53% | 1,326,000 +330,000 | +33% | +$3.92M |
|
|
23
Teva Pharmaceuticals
TEVA
$21.1B
| $15.4M | 1.49% | 291,636 -550,100 | -65% | -$29.1M |
|
|
PTX
24
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $15M | 1.45% | +3,500,000 | New | +$15M |
|
|
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
| $14.6M | 1.42% | 5,137,645 -737,631 | -13% | -$2.1M |
|